{"id":"placebo-of-hepalatide","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4650398","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this formulation contains no active pharmaceutical ingredient and serves as a control comparator in clinical studies to assess the efficacy and safety of Hepalatide itself. Placebos are essential for blinded trial designs to distinguish true drug effects from placebo response and natural disease progression.","oneSentence":"This is a placebo control formulation used in clinical trials and does not exert any active pharmacological effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:05.293Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07309380","phase":"PHASE3","title":"Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D","status":"NOT_YET_RECRUITING","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Hepatitis D, Chronic","enrollment":150},{"nctId":"NCT04426968","phase":"PHASE2","title":"A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2021-06-18","conditions":"Hepatitis B, Chronic","enrollment":96},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT05827146","phase":"PHASE2","title":"Study of Hepalatide in Chronic Hepatitis D(CHD) Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2023-10-07","conditions":"Chronic Hepatitis D Infection","enrollment":23},{"nctId":"NCT04662164","phase":"PHASE1, PHASE2","title":"A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin","status":"WITHDRAWN","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2025-12","conditions":"Type 2 Diabetes Patients","enrollment":""},{"nctId":"NCT02612506","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2015-10","conditions":"Hepatitis B， Chronic","enrollment":48},{"nctId":"NCT03023787","phase":"PHASE1","title":"Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2016-08","conditions":"Hepatitis B， Chronic","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo of Hepalatide","genericName":"Placebo of Hepalatide","companyName":"Shanghai HEP Pharmaceutical Co., Ltd.","companyId":"shanghai-hep-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}